stockrow
Saturday 7 November 2026
Export AGEN’s income statement to Excel — free account
Agenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024.
- Revenue
- +4.14%
- EPS
- −99.0%
- Free cash flow
- −37.1%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
7.13
0.69
+10.71%
Follow AGEN
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 6 | 5 | 4 |
+8 more TTM periods Free account |
| (14.99%) | (33.86%) | (23.40%) | 0.03% | ||
| 12.29% | 51.30% | 33.31% | (0.04%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(71.00%) | (66.19%) | (46.32%) | 0.06% | |
Average Days of Receivables |
0.00 | 151.84 | 159.31 | 22.41 | |
Free Cash Flow per Share |
(1.66) | (2.37) | (2.30) | (2.58) | |
Free Cash Flow |
(103.86) | (98.16) | (87.14) | (76.84) | |
Capital Expenditures |
— | 0.35 | 0.39 | 0.35 | |
| Other line items | |||||
Cash ROIC |
499.65% | 62.50% | 53.53% | 33.38% | |
Accounts Receivable Turnover |
0.00 | 4.75 | 4.55 | 30.79 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.01 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 29,638.21 | |
Days of Inventory on Hand |
— | — | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
34.15% | 43.47% | 56.22% | 69.48% | |
Selling, General and Administrative Expense of Revenue |
26.92% | 29.00% | 36.76% | 47.63% | |
Share Based Compensation of Revenue |
8.29% | 8.60% | 9.19% | 12.06% | |
Interest Coverage |
0.86 | 0.61 | 0.14 | (0.36) | |
Operating CF/Net income |
(3.53) | (1.07) | (1.36) | 764.31 | |
Depreciation/Fixed assets |
0.16 | 0.33 | 0.49 | 0.65 | |
Capex/Depreciation |
0.00 | 0.07 | 0.05 | 0.04 | |
Revenue per Share |
2.14 | 3.21 | 3.26 | 3.84 | |
Operating CF per Share |
(1.66) | (2.38) | (2.31) | (2.60) | |
Capex per Share |
0.00 | 0.01 | 0.01 | 0.01 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026